GF Joos, J Van Schoor, JC Kips and RA Pauwels
Department of Respiratory Diseases, University Hospital, Ghent, Belgium.

The tachykinins substance P and neurokinin A (NKA) are present in sensory airway nerves and have been implicated in the pathogenesis of asthma. FK224 is a cyclopeptide tachykinin antagonist previously shown to inhibit both tachykinin NK-1 and NK-2 receptor mediated airway responses in guinea pigs. Inhaled FK224 protected against bradykinin- induced bronchoconstriction and cough in asthmatics. In this study we examined the reproducibility of the NKA challenge and the effect of inhaled FK224 on NKA-induced bronchoconstriction in 10 patients with stable asthma. On Day 1 baseline lung function and PC20 methacholine were determined. On Days 2 and 3 increasing doubling concentrations of NKA (3.3 x 10(-9) to 1.0 x 10(-6) mol/ml) were administered via inhalation, with intervals of 10 min. On both days NKA caused a concentration-dependent decrease in specific airways conductance (sGaw) and FEV1. Mean +/- SEM, log PC35, sGaw NKA (mol/ml) was -6.61 +/- 0.10 on Day 2 and -6.57 +/- 0.14 on Day 3 (not significant [NS]). On Days 4 and 5 FK224 (4 mg) or placebo (P) was administered via metered-dose inhaler 30 min before NKA challenge in a double-blind, crossover manner. The study medication was well tolerated. FK224 had no significant effect on baseline lung function. After P and FK224, NKA caused a comparable concentration-dependent bronchoconstriction. The mean +/- SEM log PC35 sGaw NKA (mol/ml) was -6.04 +/- 0.18 after P and - 6.19 +/- 0.23 after FK224 (NS). In conclusion, inhaled FK224 had no effect on baseline lung function and offered no protection against NKA- induced bronchoconstriction in a group of mild asthmatic patients.

This article has been cited by other articles:

				J. D. Boot, S. de Haas, S. Tarasevych, C. Roy, L. Wang, D. Amin, J. Cohen, P. J. Sterk, B. Miller, A. Paccaly, et al. Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 450 - 457. [Abstract] [Full Text] [PDF]

				G.F. Joos, W. Vincken, R. Louis, V.J. Schelfhout, J.H. Wang, M.J. Shaw, G.D. Cioppa, and R.A. Pauwels Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Eur. Respir. J., January 1, 2004; 23(1): 76 - 81. [Abstract] [Full Text] [PDF]

				G.F. Joos and B. O'Connor Indirect airway challenges Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068. [Abstract] [Full Text] [PDF]

				A. N. Freed, S. McCulloch, T. Meyers, and R. Suzuki Neurokinins Modulate Hyperventilation-induced Bronchoconstriction in Canine Peripheral Airways Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1102 - 1108. [Abstract] [Full Text] [PDF]

				K. MAGHNI, R. TAHA, W. AFIF, Q. HAMID, and J. G. MARTIN Dichotomy between Neurokinin Receptor Actions in Modulating Allergic Airway Responses in an Animal Model of Helper T Cell Type 2 Cytokine-associated Inflammation Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 1068 - 1074. [Abstract] [Full Text]

				A. de VRIES, M. C. DESSING, F. ENGELS, P. A. J. HENRICKS, and F. P. NIJKAMP Nerve Growth Factor Induces a Neurokinin-1 Receptor- Mediated Airway Hyperresponsiveness in Guinea Pigs Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1541 - 1544. [Abstract] [Full Text] [PDF]

				J. E. Sherwood, P. J. Mauser, and R. W. Chapman Bronchoconstrictor and Respiratory Effects of Neurokinin A in Dogs J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 788 - 793. [Abstract] [Full Text]